3-苯基-2-糠酸甲酯 | 71237-44-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 中文名称: 3-苯基-2-糠酸甲酯
• 英文名称: methyl 3-phenyl-2-furoate
• 英文别名: Methyl-3-phenyl-2-furoat；3-phenyl-furan-2-carboxylic acid methyl ester；3-Phenyl-furan-2-carbonsaeure-methylester；3-phenyl-2-furancarboxylic acid, methyl ester；Methyl 3-phenylfuran-2-carboxylate
• CAS: 71237-44-0
• 化学式: C₁₂H₁₀O₃
• mdl: MFCD22578568
• 分子量: 202.21
• InChiKey: NCUSDJQPBORFOB-UHFFFAOYSA-N

物化性质

• 熔点：
  63.5-64.5 °C
• 沸点：
  147-172 °C(Press: 10 Torr)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  39.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-苯基-2-糠酸甲酯 生成 3-苯基呋喃-2-羧酸
  参考文献：
  名称：

  雌三醇的合成类似物的制备

  摘要：

  已经制备了用于Striga和Orobanche属的寄生杂草的天然发芽刺激剂strigol的一系列类似物。大多数产物包含通过烯醇-醚键连接至but-2-enolide的5-位的α-甲酰基-γ-内酯（或α-甲酰基-γ-内酰胺）基团。有些已经显示出足够高的活动量，可以进行大规模的现场试验。

  DOI：

  10.1039/p19810001734
• 作为产物：
  描述：

  2,3-epoxy-5,5-dimethoxy-3-phenyl-valeric acid methyl ester 以85%的产率得到3-苯基-2-糠酸甲酯
  参考文献：
  名称：

  3-Substituted-(5-arylfuran-2-ylcarbonyl)guanidines as NHE-1 inhibitors

  摘要：

  The C-3 substituents effect on NHE-1 inhibitory activity of (5-arylfuran-2-ylcarbonyl)guanidines, previously identified as potent NHE-1 inhibitors, was investigated. The introduction of amine or alkyl groups at the 3-position of the furan ring, next to the acylguanidine moiety, remarkably improves NHE-1 inhibitory potency. Especially the important finding is that 5-(2,5-dichloro)phenyl and 5-(2-methoxy-5-chloro)phenyl derivatives exhibit high NHE-1 inhibitory activities (IC50 < 0.02 microM) that match those of 3-unsubstituted derivatives.

  DOI：

  10.1016/j.bmcl.2006.12.012

文献信息

• Substituted furan compounds and pharmaceutical compositions containing
  申请人：Glaxo Group Limited

  公开号：US04288443A1

  公开（公告）日：1981-09-08

  The invention relates to compounds of the general formula ##STR1## and physiologically acceptable salts and N-oxides, hydrates and bioprecursors thereof, in which R.sub.1 and R.sub.2 which may be the same or different each represent hydrogen, C.sub.1-8 alkyl, C.sub.4-8 cycloalkyl, C.sub.3-6 alkenyl, aralkyl with 1 to 4 carbon atoms in the alkyl residue or C.sub.1-8 alkyl interrupted by an oxygen atom or a group ##STR2## in which R.sub.5 represents hydrogen or C.sub.1-8 alkyl, or R.sub.1 and R.sub.2 may together with the nitrogen atom to which they are attached, form a saturated monocyclic 5 to 7 membered heterocyclic ring which may additionally contain the heterofunction O or ##STR3## R.sub.3 represents straight or branched chain C.sub.1-8 alkyl, alkoxyalkyl with 1 to 8 carbon atoms in each alkyl residue, C.sub.1-8 hydroxyalkyl, C.sub.1-8 alkoxycarbonyl, alkyl thioalkyl with 1 to 8 carbon atoms in each alkyl residue, halogen or aryl; R.sub.4 represents hydrogen, C.sub.1-8 alkyl, C.sub.3-6 alkenyl or alkoxyalkyl with 1 to 8 carbon atoms in each alkyl residue; X represents --O-- or --S--; Y represents .dbd.S, .dbd.O, .dbd.NR.sub.6 or .dbd.CHNO.sub.2 where R.sub.6 represents hydrogen, nitro, cyano, C.sub.1-8 alkyl, aryl, C.sub.1-8 alkylsulphonyl or arylsulphonyl; m represents an integer from 2 to 4 inclusive; and n represents an integer which is 1 or 2, or additionally when X is --S-- n may also be zero. The invention also relates to processes for the production of such compounds, pharmaceutical compositions containing them and certain novel intermediates used in their production, i.e. amines of the formula ##STR4## and alcohols of the formula ##STR5## The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.

  该发明涉及一般公式##STR1##的化合物，以及其生理上可接受的盐和N-氧化物、水合物和生物前体，其中R.sub.1和R.sub.2可以相同也可以不同，每个代表氢、C.sub.1-8烷基、C.sub.4-8环烷基、C.sub.3-6烯基、含有1至4个碳原子的烷基残基的芳基烷基或被氧原子或基团##STR2##打断的C.sub.1-8烷基，其中R.sub.5代表氢或C.sub.1-8烷基，或者R.sub.1和R.sub.2可以与它们连接的氮原子一起形成饱和的单环5到7成员杂环环，还可以额外含有杂原子O或##STR3##，R.sub.3代表直链或支链C.sub.1-8烷基、在每个烷基残基中含有1至8个碳原子的烷氧烷基、C.sub.1-8羟基烷基、C.sub.1-8烷氧羰基、在每个烷基残基中含有1至8个碳原子的烷基硫烷基、卤素或芳基；R.sub.4代表氢、C.sub.1-8烷基、C.sub.3-6烯基或在每个烷基残基中含有1至8个碳原子的烷氧烷基；X代表--O--或--S--；Y代表.dbd.S、.dbd.O、.dbd.NR.sub.6或.dbd.CHNO.sub.2，其中R.sub.6代表氢、硝基、氰基、C.sub.1-8烷基、芳基、C.sub.1-8烷基磺酰基或芳基磺酰基；m表示一个从2到4的整数；n表示一个整数，可以是1或2，或者当X为--S--时，n也可以为零。该发明还涉及生产这种化合物的过程，含有它们的药物组合物以及在其生产中使用的某些新颖中间体，即一般式##STR4##的胺和一般式##STR5##的醇。式(I)的化合物显示作为选择性组织胺H.sub.2-拮抗剂的药理活性。
• Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose
  申请人：Alcon Laboratories, Inc.

  公开号：US05153211A1

  公开（公告）日：1992-10-06

  Disclosed are substituted or unsubstituted planar tricyclic fluorene or nuclear analogs thereof, spiro-coupled to a five-membered ring containing a secondary amide, and the pharmaceutically acceptable salts thereof. These compounds are useful, inter alia in the treatment of diabetes. Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when indicated for, inter alia, long term, prophylactic treatment of the diabetes syndrome. A particularly preferred class of compounds comprise difluoro-dialkoxy substituted spiro-(9H-fluorene-9,4'-imidazolidine)-2',5-diones.

  本发明涉及取代或未取代的平面三环芴或其核类似物，与含有次级酰胺的五元环螺合，以及其药学上可接受的盐。这些化合物在糖尿病的治疗中有用。本发明还涉及制备这些化合物的方法；包含这些化合物的制药组合物；以及在适用于糖尿病综合症的长期预防性治疗等情况下，通过给予这些化合物和组合物进行治疗的方法。一种特别优选的化合物类别包括二氟二烷氧基取代的螺-(9H-芴-9,4'-咪唑啉)-2',5-二酮。
• Spiro-tricyclicaromatic succinimide derivatives
  申请人：Alcon Laboratories, Inc.

  公开号：US05070100A1

  公开（公告）日：1991-12-03

  Disclosed are substituted or unsubstituted planar tricyclic fluorene or nuclear analogs thereof, spiro-coupled to a five-membered ring containing a secondary amide, and the pharmaceutically acceptable salts thereof. These compounds are useful, inter alia in the treatment of diabetes. Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when indicated for, inter alia, long term, prophylactic treatment of the diabetes syndrome. A particularly preferred class of compounds comprise difluoro-dialkoxy substituted spiro-(9H-fluorene-9,4'-imidazolidine)-2,40 ,5-diones.

  本发明涉及取代或未取代的平面三环芴或其核类似物，与含有二级酰胺的五元环螺合的化合物以及其药学上可接受的盐。这些化合物可用于治疗糖尿病等疾病。本发明还涉及制备这些化合物的方法；包含这些化合物的制药组合物；以及在适当时用于长期预防性治疗糖尿病综合症等情况下，通过给予这些化合物和组合物的治疗方法。其中一类特别优选的化合物包括二氟二烷氧基取代的螺-(9H-芴-9,4'-咪唑啉)-2,4,5-二酮。
• [EN] CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF<br/>[FR] MODULATEURS DE CALPAIN ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：BLADE THERAPEUTICS INC

  公开号：WO2018064119A8

  公开（公告）日：2019-04-25
• β-Keto Acetals. II. Synthesis of 3-Methyl- and 3-Phenyl-furans
  作者：D. M. BURNESS

  DOI：10.1021/jo01107a021

  日期：1956.1

表征谱图